The crosstalk between long non-coding RNAs and the hedgehog signaling pathway in cancer

Sargazi, Marzieh Lotfian; Jafarinejad-Farsangi, Saeideh; Moazzam-Jazi, Maryam; Rostamzadeh, Farzaneh; Karam, Zahra Miri

doi:10.1007/s12032-022-01710-2

Cited by 6 publications

(2 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 507 LncRNA can regulate HH signaling pathway through activation or inhibition, which is related to tumor initiation or progression, chemotherapy resistance, recurrence and other processes. 508 The diagnosis or treatment methods based on lncRNA are promising. In Table 4 , we summarized ncRNAs that inhibit cancer development through HH signaling pathway.…”

Section: Targeted Therapies Of Hh Signaling In Cancersmentioning

confidence: 99%

Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies

Jing,

Wu,

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

The past decade has seen significant advances in our understanding of Hedgehog (HH) signaling pathway in various biological events. HH signaling pathway exerts its biological effects through a complex signaling cascade involved with primary cilium. HH signaling pathway has important functions in embryonic development and tissue homeostasis. It plays a central role in the regulation of the proliferation and differentiation of adult stem cells. Importantly, it has become increasingly clear that HH signaling pathway is associated with increased cancer prevalence, malignant progression, poor prognosis and even increased mortality. Understanding the integrative nature of HH signaling pathway has opened up the potential for new therapeutic targets for cancer. A variety of drugs have been developed, including small molecule inhibitors, natural compounds, and long non-coding RNA (LncRNA), some of which are approved for clinical use. This review outlines recent discoveries of HH signaling in tissue homeostasis and cancer and discusses how these advances are paving the way for the development of new biologically based therapies for cancer. Furthermore, we address status quo and limitations of targeted therapies of HH signaling pathway. Insights from this review will help readers understand the function of HH signaling in homeostasis and cancer, as well as opportunities and challenges of therapeutic targets for cancer.

show abstract

Section: Targeted Therapies Of Hh Signaling In Cancersmentioning

confidence: 99%

Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies

Jing,

Wu,

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…As observed, various signaling cascades can be involved at the Gli level (Type III), such as RAS-RAF-MEK-ERK [134,135], PI3K/AKT/mTOR [136][137][138], TGFβ [139,140], DYRK family [141], BET proteins, and oncogenic drivers (EWS/FLI1, SOX9 FOXC1, c-MYC) [142][143][144][145], which are involved in optimizing Gli activity [146]. Apparently, the activity of Gli can be adversely affected by tumor suppressors (p53, NUMB, SNF5) [147][148][149], MAPKKK/MEKK [150,151], and miRNAs (miR-324-5p, miR-361, miR-326) [152][153][154] in Smo-independent Hh signaling appear to be a fallback activation pathway in canonical Hh signaling and a way for cells to evade the classical Hh pathway to activate downstream gene expression in response to abnormal environmental stress.…”

Section: The Canonical and Noncanonical Hh Signaling Pathwaysmentioning

confidence: 99%

The role of Hedgehog and Notch signaling pathway in cancer

Xia

Yang

et al. 2022

Mol Biomed

View full text Add to dashboard Cite

Notch and Hedgehog signaling are involved in cancer biology and pathology, including the maintenance of tumor cell proliferation, cancer stem-like cells, and the tumor microenvironment. Given the complexity of Notch signaling in tumors, its role as both a tumor promoter and suppressor, and the crosstalk between pathways, the goal of developing clinically safe, effective, tumor-specific Notch-targeted drugs has remained intractable. Drugs developed against the Hedgehog signaling pathway have affirmed definitive therapeutic effects in basal cell carcinoma; however, in some contexts, the challenges of tumor resistance and recurrence leap to the forefront. The efficacy is very limited for other tumor types. In recent years, we have witnessed an exponential increase in the investigation and recognition of the critical roles of the Notch and Hedgehog signaling pathways in cancers, and the crosstalk between these pathways has vast space and value to explore. A series of clinical trials targeting signaling have been launched continually. In this review, we introduce current advances in the understanding of Notch and Hedgehog signaling and the crosstalk between pathways in specific tumor cell populations and microenvironments. Moreover, we also discuss the potential of targeting Notch and Hedgehog for cancer therapy, intending to promote the leap from bench to bedside.

show abstract